Patients and tumor samples
tumor, PAOLA-1 BRCAwt tumors
TUMOR
The first cohort consisted of FFPE-derived DNA from 449 AOC samples from the PAOLA-1/ENGOT-ov25 trial in the frame of the EHEI. The procedure consisted in preliminary evaluation of the academic test performance on 85 PAOLA-1 BRCAwt tumors by comparing to the Myriad MyChoice diagnostics, followed by final PFS based test evaluation on 364 additional patient samples (phase 3) [The second cohort consisted of 109 consecutive FFPE AOC samples (8 to 20 slides of 5 µm according to the tumor area) sent to Myriad Genetics central laboratory (Salt Lake City, UT, USA), from March 2021 to January 2022, as part of the routine clinical management process. All patients have a recent diagnosis of high grade AOC and the samples contained more than 30% of tumor cells. The third cohort consisted of 31 consecutive FFPE AOC samples issued from the routine laboratory of Poitiers Hospital previously analyzed by MyChoice test in Myriad Genetics central laboratory. 